Case report

TRMT10A mutation in a child with diabetes, short stature, microcephaly and hypoplastic kidneys

Running title: Diabetes due to TRMT10A mutation

Eve Stern1,2, Asaf Vivante2,3, Ortal Barel2,4, Yael Levy-Shraga1,2
1Pediatric Endocrinology and Diabetes Unit, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel
2The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Department of Pediatrics B and Pediatric Nephrology Unit, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel
4The Genomic Unit, Sheba Cancer Research Center, Tel-Hashomer, Israel

What is already known on this topic?
Over 40 different genetic subtypes of monogenic diabetes have been identified to date. TRMT10A mutations cause a distinct syndrome that includes abnormal glucose homeostasis, intellectual disability, short stature and microcephaly.

What this study adds?
Our report expands the phenotypic description of this syndrome. We reported for the first time hypoplastic kidneys and inadequate response to growth hormone stimulation tests in a girl with this syndrome. Making a specific molecular diagnosis helps to predict the clinical course and enable genetic counseling as well as personalized treatment.

Abstract
A new syndrome of diabetes, short stature, microcephaly and intellectual disability has been described in association with mutations in the tRNA methyltransferase 10 homologue A (TRMT10A) gene. We report a patient who presented with fasting hyperglycemia, a raised HbA1C and positive islet cell autoantibodies. Additional clinical features included intellectual disability, hypoplastic kidneys and short stature. In view of syndromic features alongside diabetes, genetic evaluation was carried out revealing a homozygous mutation in the TRMT10A gene (c.616G>A, p.G206R). The case highlights the importance of genetic evaluation of patients with diabetes with atypical features that can further progress our understanding of the pathophysiology of the rarer subtypes of diabetes.

Keywords: Monogenic diabetes; short stature; microcephaly; hypoplastic kidneys

Correspondence: Yael Levy-Shraga, M.D., The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel-Hashomer, 52621 Israel. Tel: 972-3-5305015, Fax: 972-3-5305055
e-mail: yael.levy.shraga@gmail.com
25.11.2020
28.12.2020
0000-0002-8603-4230
Introduction
Monogenic diabetes is uncommon, accounting for approximately 1% to 6% of pediatric diabetes patients (1, 2). The disease may be inherited within families as a dominant or recessive trait, and rarely as mitochondrial inheritance. It may also present as a spontaneous case due to a de novo mutation. Over 40 different genetic subtypes of monogenic diabetes have been identified to date, each having a typical phenotype and a specific pattern of inheritance. MODY (maturity onset diabetes of the young) is by far the commonest type of monogenic diabetes. All currently known subtypes of MODY are caused by dominant heterozygous mutations in genes important for the development or function of β-cells (3). Over the last few years, a number of forms of monogenic diabetes clinically and genetically distinct from MODY have been identified.

In 2013, a new autosomal recessive syndrome including short stature, microcephaly, intellectual disability and diabetes mellitus was described in association with mutations in the tRNA methyltransferase homologue A (TRMT10A) gene (4). Since the first description, only few case reports with this syndrome have been published (5-9).

The aim of this case report is to describe a girl that presented with hyperglycemia and positive autoantibodies with a presumed diagnosis of type 1 diabetes. Identification of the genetic etiology of a TRMT10A mutation improved the understanding of the disease course and enabled personalized clinical care.

Case report
An 11-year-old girl was referred to the emergency room in light of high fasting glucose (153 mg/dl, normal values 70-100) and an HbA1C of 9.9% (normal values 3.8-6.4).

The patient was born to Jewish parents of Uzbekistan descent; parents were distantly related. Two older siblings were healthy and there was no family history of diabetes or any other autoimmune condition. Pregnancy was notable for intrauterine growth retardation (IUGR) demonstrated from week 17 of pregnancy. Birth weight was 2190 grams at term with no perinatal complications. Developmental milestones were delayed and the patient had been diagnosed with attention deficit disorder in early childhood.

At the age of two years old following repeated urinary tract infections, an ultrasound scan revealed bilateral mildly hypoplastic kidneys. Consequently, she was under nephrology follow-up that showed stable renal growth and normal renal function.

At the age of 11 years, her height was 127.3 cm (-2.3 SD), weight 33.5 kg (-0.5 SD), BMI 20.7 kg/m² (1.0 SD) and head circumference 49 cm (-2.0 SD) (Figure 1). Growth velocity was 4.2 cm/year. Due to the short stature the patient was referred for endocrinological assessment. Laboratory investigations revealed fasting blood glucose of 110 mg/dl (normal values 70-100) and insulin-like growth factor 1 (IGF1) 168 ng/ml (normal range 118-448). Her Bone age determined using the Greulich-Pyle method was eight years and ten months at chronological age of ten years and nine months. On repeat laboratory investigations, fasting blood glucose was 153 mg/dl and HbA1C 9.9% (normal values 3.8-6.4). Medical history was negative for polydipsia, polyuria or significant weight loss. Subsequent laboratory exams showed positive anti-islet cell antibodies (76.9, normal range 0-30) with weakly positive anti-GAD antibodies (7.4, normal range 0-5). She was started on a low dose of long acting insulin with a working diagnosis of type 1 diabetes.

In view of the combination of IUGR, developmental delay, hypoplastic kidneys, short stature and diabetes, a genetic etiology was suspected. The presence of hypoplastic kidneys raised the suspicion for a diagnosis of MODY type 5, which can include congenital renal malformations as a feature. Therefore, she was referred the nephro-genetic clinic in our institute. On examination dysmorphic features including microcephaly, narrow nasal bridge, retrognathia and beaked nose were observed. In addition, a large hyperpigmented skin lesion on her left thigh and bilateral fifth finger clinodactyly were noted. Microarray was reported as normal. Whole exome sequencing was carried out which revealed a homozygous missense mutation in the TRMT10A gene (NM_001134665, c.616G>A, p.G206R). This mutation has previously been reported (5). Both parents were found to be heterozygous for the mutation. Growth hormone stimulations tests were performed due to short stature, low growth velocity and delayed bone age. Peak growth hormone was 7.3 mcg/l after administration of Clonidine and 1.8 mcg/l after administration of Arginine, establishing a diagnosis of growth hormone deficiency. MRI of the pituitary was reported as normal. Growth hormone replacement therapy was discussed with the family who decided against treatment.

In the subsequent months following diagnosis, glucose levels were well controlled with low doses of long acting insulin with no need for boluses of short acting insulin with meals. Subsequently short acting insulin was started with meals.

Two years following diagnosis, she was clinically well. Her height was 139.5 cm (-2.5 SD), weight 43.3 kg (-0.3 SD) and BMI 22.4 kg/m² (1.0 SD) (Figure 1). Pubertal status was Tanner stage 3. The insulin requirement was 0.4 units/kg/day. Glycemic control was good with fasting glucose 147 mg/dl and HbA1C of 7%. C-peptide level at the same time was still detectable at 2.47 ng/ml (normal range 0.9-7.1). Monitoring glucose levels using the FreeStyle Libre flash glucose monitoring system demonstrated relatively stable glucose levels with no hypoglycemic events (Figure 2). Ophthalmic examination was normal with no evidence of retinopathy.

Informed consent from the parents of the patient was obtained.

Discussion
Here we present a case of monogenic diabetes due to TRMT10A mutation. The elevated fasting glucose and HbA1C of the patient met the criteria for a diagnosis of diabetes mellitus. Diabetes mellitus is a heterogeneous group of disorders with different genetic patterns and pathophysiological mechanisms. Type 1 diabetes is the most common type in the pediatric population and the patient had positive anti-islet cell antibodies. However, the low insulin requirements, detectable C-peptide levels and presence of extra pancreatic features (IUGR, developmental delay, hypoplastic kidneys, short stature) raised the suspicion of a genetic syndrome. The presence of hypoplastic kidneys was suspicious for a diagnosis of MODY type 5; however, no mutation in HNF1β was detected on whole exome sequencing. Type 2 diabetes is becoming an increasing problem in obese adolescents but the patient’s BMI was in the normal range for her age. TRMT10A mutation was first described in three siblings born to consanguineous parents of Moroccan descent, each with short stature and intellectual disability. They were diagnosed with diabetes between ages 14-22 years (4). All were negative for anti-GAD, islet cell and anti-insulin antibodies in addition to having an HLA phenotype that did not confer risk of developing Type 1 Diabetes. Whole exome sequencing was carried out on one of the probands and one candidate mutation in chromosome 4, a homozygous c.379G>A in exon 4 of TRMT10A was identified. Following this report, nine additional individuals from five different families were reported as having homozygous mutations, compound heterozygous or deletion in the same gene (5-9). Similar to our patient, all reported patients exhibited intellectual disability and microcephaly (Table 1). In some patients the microcephaly presented at birth and resolved later and others had persistent microcephaly. Some patients had epilepsy and two patients had abnormal brain MRI findings (6).

Another main feature of the syndrome is abnormal glucose homeostasis. A variety of clinical presentations have been reported, including diabetes with or without ketosis, hyperinsulinemic hypoglycemia, insulin resistance and postprandial hyperglycemia. The age at diabetes diagnosis ranged from nine to 28 years. Our patient was diagnosed with diabetes at the age of 11 years without ketoacidosis. Interestingly, she had positive islet cell antibodies, as was previously described in another patient (7). She had good glycemic control with relatively low insulin doses (0.4 units/kg/day) and detectable c-peptide two years after the diagnosis. This feature of well-preserved insulin secretion was previously reported in this syndrome (4, 7, 8). Of note, our patient had the same mutation as the family described by Gillis et al (5). Both families originated from the same small and isolated Jewish community in Uzbekistan, yet, the clinical phenotype differed between the two families. The three siblings had mainly hyperinsulinemic hypoglycemia (5), while our patient had diabetes with no documented hypoglycemic events. Our novel finding is the hypoplastic kidneys and abnormal growth hormone stimulation tests, that were not previously described. Although short stature was previously described as part of this syndrome, this is the first time that growth hormone deficiency was diagnosed by stimulation tests. Additional features of the syndrome that were described in some of the patients included dysmorphic features and delayed puberty.

Transfer RNAs (tRNAs) are non-coding RNA molecules essential for protein synthesis (10). Across many species, tRNAs undergo complex post translational modifications including modification of tRNA nucleotide bases and sugars crucial for cellular function. Multiple enzymes have been identified that catalyze these posttranscriptional tRNA modification reactions. TRMT10A encodes a protein that has tRNA m^G9 methyltransferase activity (6). The protein was first discovered in yeast and its homologues are widely conserved across eukarya and archaea (11). The functional characterization of human TRMT10A was recently studied (12). This nuclear protein is expressed in several tissues including the liver, kidney, spleen, lung and adipose tissue. The expression is enriched in the brain and pancreatic islet cells. This is consistent with the main features of the syndrome described: microcephaly, intellectual disability and abnormal glucose homeostasis. TRMT10A silencing has been shown to induce apoptosis, which suggests that mutations may negatively affect beta cell mass and the number of neurons in the developing brain (4).

In summary, our report expands the phenotypic description of this syndrome. This case demonstrates that genetic testing should be performed in those diabetic patients with preserved β-cell function over an extended period or with extra-pancreatic features. Further studies are needed to shed light on the pathogenesis resulting from TRMT10A inactivation.

References
Table 1: Clinical characteristics of 13 patients from seven families with TRMT10A mutations

<table>
<thead>
<tr>
<th>Reference</th>
<th>No.</th>
<th>Gender</th>
<th>TRMT10A mutation</th>
<th>Impaired glucose metabolism</th>
<th>Treatment</th>
<th>Microcephaly</th>
<th>Intellectual disability</th>
<th>Epilepsy</th>
<th>Short stature</th>
<th>Other features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Igoillo-Esteve et al, 2013 (4)</td>
<td>1</td>
<td>F</td>
<td>c.379 G&gt;A; p. Arg127Stop</td>
<td>diabetes</td>
<td>Insulin</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>Dysmorphic features, osteoporosis</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>F</td>
<td>c.379 G&gt;A; p. Arg127Stop</td>
<td>diabetes</td>
<td>Insulin</td>
<td>yes</td>
<td>yes</td>
<td>NR</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>M</td>
<td>c.379 G&gt;A; p. Arg127Stop</td>
<td>diabetes</td>
<td>Insulin</td>
<td>yes</td>
<td>yes</td>
<td>NR</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Gillis et al, 2014 (5)</td>
<td>4</td>
<td>F</td>
<td>c.616G&gt;A; p. Gly206Arg</td>
<td>hyperinsulaemic hypoglycemia and postprandial hyperglycemia,</td>
<td>diet</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>Delayed puberty</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>M</td>
<td>c.616G&gt;A; p. Gly206Arg</td>
<td>As his sister</td>
<td>diet</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>M</td>
<td>c.616G&gt;A; p. Gly206Arg</td>
<td>As his sister</td>
<td>diet</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Zung et al, 2015 (8)</td>
<td>7</td>
<td>F</td>
<td>4q23 deletion</td>
<td>Ketotic diabetes. Positive islet cell antibodies.</td>
<td>insulin</td>
<td>yes</td>
<td>yes</td>
<td>NR</td>
<td>yes</td>
<td>Delayed puberty</td>
</tr>
<tr>
<td>Yew et al, 2016 (7)</td>
<td>8</td>
<td>F</td>
<td>c.79G&gt;T; p. Glu27Ter</td>
<td>Diabetes, insulin resistance</td>
<td>metformin</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>Buffalo hump</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>M</td>
<td>c.79G&gt;T; p. Glu27Ter</td>
<td>Diabetes, insulin resistance</td>
<td>metformin</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>Delayed puberty</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>M</td>
<td>c.277C&gt;T, p. Arg93* and c.397C&gt;T, p. Arg133*</td>
<td>no</td>
<td>-</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>NR</td>
<td>Pulmonary infections, abnormal brain MRI</td>
</tr>
<tr>
<td>Lin et al, 2020 (9)</td>
<td>12</td>
<td>M</td>
<td>c.496–1G&gt;A</td>
<td>diabetes</td>
<td>metformin</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td></td>
</tr>
<tr>
<td>Present report</td>
<td>13</td>
<td>F</td>
<td>c.616G&gt;A; p. Gly206Arg</td>
<td>diabetes</td>
<td>Insulin</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>IUGR, Dysmorphic features, growth hormone deficiency, hypoplastic kidneys</td>
</tr>
</tbody>
</table>

F-female, M-male, NR-not reported, IUGR – intrauterine growth retardation


Figure 1: Height (A) and weight (B) curves of the patient
Figure 2: Averaged diurnal glucose levels within two weeks as measured by continuous glucose monitoring (Libre) two years after the diagnosis. At that time the daily insulin dose was 0.4 units/kg/day. The dark gray area represents the inter quantile range (IQR 25-75) of glucose levels and the black line the median.